

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



Figure 1: Sedation Model




Figure 2: Ventilatory Depression Model




Figure 3: Device Model




Figure 4: Pharmacokinetic Model







Figure 5A**Device Model 5010****Pharmacokinetic Model 5020**

Figure 5B

Ventilatory Depression Model 5030



Sedation Model 5040





Figure 6



7/27


Figure 7


Figure 8**9/27**




Figure 9**10/27**

Figure 10

11/27

Figure 11



12/27

Figure 12: Two Opioid Model




Figure 13A: The elements of the invention, wherein two opioids are administered through inhalation.





Figure 13B The elements of the invention, wherein two opioids are administered through inhalation.

Continued from 13A



Two Drug Model, 13050




Figure 13C The elements of the invention, wherein two opioids are administered through inhalation.





Figure 14: Drug in inhaler and lung in the presence of opioid-induced ventilatory depression and sedation for the two opioid model.




Figure 15: The rapidly acting opioid concentration in the effect site, the slowly acting opioid concentration in the effect site, and the combined concentration of opioid at the effect site, during two opioid administration with the device.






Figure 16: Ventilatory depression in the presence of self-limitation of opioid delivery from ventilatory depression and sedation with the two-opioid delivery system.



19/27

Figure 17A: The elements of the invention, wherein two opioids are administered through inhalation, and the rapidly acting opioid is alfentanil, and the slowly acting opioid is morphine.



20/27

Figure 17B: The elements of the invention, wherein two opioids are administered through inhalation, and the rapidly acting opioid is alfentanil, and the slowly acting opioid is morphine.






Figure 17C: The elements of the invention, wherein two opioids are administered through inhalation, and the rapidly acting opioid is alfentanil, and the slowly acting opioid is morphine.

Two Drug Model, 17050



Sedation Model 5040



Ventilatory Depression Model 5030





Figure 18: Alfentanil, morphine, and combined opioid effect site concentrations.



23/27






Figure 19

24/27

**Figure 20A****Figure 20B**




Figure 21

26/27

Figure 22: Correlation of side effect to toxic event

No side effect		Side effect	
N	26	24	
No hypoxia	22	14	36
Hypoxia	4	10	14
Null effect			
No hypoxia	18.72	17.28	36
Hypoxia	7.28	6.72	14
P value	0.038653124		

27/27